{"id":"NCT04796896","sponsor":"ModernaTX, Inc.","briefTitle":"A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age","officialTitle":"A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-03-15","primaryCompletion":"2024-03-15","completion":"2024-03-15","firstPosted":"2021-03-15","resultsPosted":"2025-06-13","lastUpdate":"2025-06-13"},"enrollment":11942,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["SARS-CoV-2"],"interventions":[{"type":"BIOLOGICAL","name":"mRNA-1273","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.214","otherNames":[]}],"arms":[{"label":"mRNA-1273","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an optional booster dose (BD) (in Parts 1 and 2).","primaryOutcome":{"measure":"Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)","timeFrame":"7 days post-vaccination","effectByArm":[{"arm":"Part 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μg","deltaMin":216,"sd":null},{"arm":"Part 1 (6-11 Years): PS mRNA-1273 100 μg - BD 25 μg","deltaMin":221,"sd":null},{"arm":"Part 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μg","deltaMin":93,"sd":null},{"arm":"Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μg","deltaMin":24,"sd":null},{"arm":"Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 10 μg","deltaMin":46,"sd":null},{"arm":"Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 25 μg","deltaMin":7,"sd":null},{"arm":"Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 25 μg","deltaMin":36,"sd":null},{"arm":"Part 2 (6 Months-5 Yrs): PS PBO - mRNA-1273 25 μg - BD 25 μg","deltaMin":4,"sd":null},{"arm":"Part 2 (6 Months-5 Years): PS mRNA-1273 25 μg - BD 25 μg","deltaMin":12,"sd":null},{"arm":"Part 2(6-11 Yrs): PS Placebo - mRNA-1273 50 μg - BD 1273 25 μg","deltaMin":358,"sd":null},{"arm":"Part 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μg","deltaMin":1726,"sd":null},{"arm":"Part 3 (6-11 Years): BD mRNA-1273 25 µg","deltaMin":30,"sd":null},{"arm":"Part 1 (6-11 Years): mRNA-1273 50 µg","deltaMin":374,"sd":null},{"arm":"Part 1 (6-11 Years): mRNA-1273 100 µg","deltaMin":367,"sd":null},{"arm":"Part 1 (2-5 Years): mRNA-1273 25 µg","deltaMin":62,"sd":null},{"arm":"Part 1 (2-5 Years): mRNA-1273 50 µg","deltaMin":147,"sd":null},{"arm":"Part 1 (6-23 Months): mRNA-1273 25 µg","deltaMin":141,"sd":null},{"arm":"Part 2 (6-11 Years): Placebo","deltaMin":823,"sd":null},{"arm":"Part 2 (6-11 Years): mRNA-1273 50 µg","deltaMin":2983,"sd":null},{"arm":"Part 2 (2-5 Years): Placebo","deltaMin":797,"sd":null},{"arm":"Part 2 (2-5 Years): mRNA-1273 25 µg","deltaMin":2800,"sd":null},{"arm":"Part 2 (6-23 Months): Placebo","deltaMin":596,"sd":null},{"arm":"Part 2 (6-23 Months): mRNA-1273 25 µg","deltaMin":1889,"sd":null},{"arm":"Part 3 (6-11 Years): mRNA-1273 25 µg","deltaMin":66,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":91,"countries":["United States","Canada"]},"refs":{"pmids":["40119775","39158584","36260859","35544369","34870630"],"seeAlso":["http://www.kidcovestudy.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":380},"commonTop":["Upper respiratory tract infection","Otitis media","Ear infection","Rhinorrhoea","Cough"]}}